

# Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer

Information for the public

Published: 21 June 2023

[www.nice.org.uk](http://www.nice.org.uk)

Pembrolizumab (Keytruda) with lenvatinib (Lenvima) is available on the NHS as a possible treatment for advanced or recurrent endometrial cancer in adults if:

- their cancer has progressed while having, or after having, platinum-based chemotherapy and
- they cannot have surgery that will cure their cancer, or radiotherapy.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on womb \(uterus\) cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Peaches Trust](#), [admin@peaches.trust.org](mailto:admin@peaches.trust.org)
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5254-0